Idiopathic Pulmonary Fibrosis (update)- Progressive Pulmonary Fibrosis

This webinar series is proposed to highlight recently approved or published clinical practice guidelines and official workshop report. This webinar on Idiopathic Pulmonary Fibrosis (update)- Progressive Pulmonary Fibrosis will provide guidance to clinicians in making accurate diagnosis and addressing progression of pulmonary fibrosis (PF) in interstitial lung diseases (ILD), other than IPF and offer insights on prompt treatment and other interventions to reduce complications and mortality.

Speakers will describe the clinical recommendations and strategies formulated by the guideline and workshop panels, discuss the rationale and critically review the evidence supporting each recommendation and strategy. 

 

  • Introduction: Ganesh Raghu, Chair - 5 min
  • Methodology: Marya  Ghazipura - 10 min
  • Update on diagnosis of Idiopathic diagnosis; diagnostic and treatment recommendations for IPF and definition of progressive pulmonary fibrosis (PPF): Ganesh Raghu - 15 min
  • Antifibrotic treatment for progressive pulmonary fibrosis: Marya Ghazipura - 10 min
  • Closing remarks: Ganesh Raghu, Chair - 5 min
  • Questions and answers - 15 min   

Learning Objectives

 

  • Discuss the diagnostic criteria and evidence-based recommendations for idiopathic pulmonary fibrosis (IPF).
  • Differentiate progressive pulmonary fibrosis (PPF) in patients with interstitial lung diseases (ILD) from IPF using the defined criteria.
  • Effectively determine evidence-based anti-fibrotic treatment strategies for PPF using nintedanib and pirfenidone.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    The American Thoracic Society designates this for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
Publication Date: 
12/05/2023
Credit Expires: 
12/05/2024
Rating: 
0

 

ACCREDITATION STATEMENT

The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DISCLOSURE DECLARATIONS

It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.

This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    The American Thoracic Society designates this for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Participation
Please login or register to take this course.

 

To start this learning activity, press the Take Activity button. Then follow the on-screen instructions.

The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.